Business Exposures
Activism
Animal Testing
Artificial Intelligence
Boeing 737
Brexit
Cannabis
Censorship
Climate
Coal
COVID-19
Criminal
Death
Debt Markets
Derivatives
Diversity
Economy
Electric Vehicles
Electricity Generation
Ethanol
Financial
Firearms
Fossil Fuels
Glyphosate
Harassement
Immigration
Information Security
Intellectual Property
Interest Rates
Labor
Layoff
Lead
Legal
Palm Oil
Pension
Political
Product Safety
Regulatory
Religion
Securities Market
Supply Chain
Tariff
Textiles
US Equities
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
99
100
Next >
Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
August 19, 2024
Via
MarketBeat
Exposures
COVID-19
Product Safety
Tickers
BNTX
MRK
MRNA
NVAX
Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Post-Traumatic Stress Disorder
August 19, 2024
Via
PressReach
Exposures
Product Safety
Tickers
ALZN
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Reports on Status of Lead Drug Candidate Designed to Treat Concussion
August 19, 2024
Via
Investor Brand Network
Exposures
Product Safety
Tickers
OGEN
The Benefits of Genetic Testing for Patients with CDKL5 Deficiency Disorder and Other Rare Genetic Epilepsies
August 14, 2024
Via
Brandpoint
Exposures
Product Safety
Steven Gillhouse Featured in Exclusive Interview on Ideamensch
August 13, 2024
Via
Get News
Topics
Product Recall
Exposures
Legal
Product Safety
FDA Allows Resumption Of BioNTech/MediLink Therapeutics Partnered Phase 1 Study For Cancer Drug With Lower Dose
August 19, 2024
Via
Benzinga
Exposures
Product Safety
Tickers
BNTX
United Health Products Submits Response Letter to FDA
August 19, 2024
Via
NewMediaWire
Exposures
Product Safety
Tickers
UEEC
FDA Rejects MDMA for Mental Health Treatment After Identifying Flawed Study Data
August 19, 2024
Via
Press Release Distribution Service
Exposures
Product Safety
Lykos Therapeutics Strategic Reorganization Following FDA's Decision Rejecting MDMA For PTSD Treatment
August 16, 2024
Via
Benzinga
Exposures
Product Safety
Incyte Seeks Expanded FDA Approval For Lymphoma Drug After Releasing Promising Topline Data From Late-Stage Study
August 16, 2024
Via
Benzinga
Exposures
Product Safety
Tickers
INCY
FDA Approves AstraZeneca's Blockbuster Cancer Drug, Imfinzi, In Combination With Chemo For Non-Small Cell Lung Cancer
August 16, 2024
Via
Benzinga
Exposures
Product Safety
Tickers
AZN
From Detroit Dreams to Hollywood Realities: Anise Fuller’s Journey with Walk By Faith Productions
August 15, 2024
Via
Small Business Trendsetters
Topics
Product Recall
Exposures
Legal
Product Safety
Why Is Small-Cap Tempest Therapeutics Stock Trading Higher On Thursday?
August 15, 2024
Via
Benzinga
Exposures
Product Safety
Tickers
RHHBY
TPST
BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q2 2024 Financial Report, Operational Update
August 15, 2024
Via
Investor Brand Network
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
Tickers
BEAT
InvestorNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) Reports on Q2 2024 Financial Results, Business Highlights
August 15, 2024
Via
Investor Brand Network
Exposures
Product Safety
Tickers
LGVN
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Publishes Q2 2024 Results
August 15, 2024
Via
Investor Brand Network
Exposures
Product Safety
Tickers
CNSP
FDA Rejects MDMA Therapy Application, Calls for More Research
August 15, 2024
Via
Investor Brand Network
Exposures
Product Safety
FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication
August 15, 2024
Via
Benzinga
Exposures
Product Safety
Tickers
INCY
SNDX
FDA Approves Gilead's Seladelpar For Inflammatory Liver Disease, Acquired Via $4B CymaBay Deal
August 15, 2024
Via
Benzinga
Exposures
Product Safety
Tickers
GILD
ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements
August 15, 2024
Via
NewMediaWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Tickers
ABVC
“Explosive Growth Stocks: Innovations, Strategy, Earners Unlock Prime Potential CXAI, OGEN, PRSO, INBS, KAVL”
August 14, 2024
Via
AB Newswire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Product Safety
Tickers
CXAI
INBS
OGEN
PRSO
Don't Promote Copycat Weight-Loss Drugs Amid Improved Supply, Eli Lilly Asks Doctors, FDA Evaluates
August 14, 2024
Via
Benzinga
Exposures
Product Safety
Tickers
LLY
NVO
Kaya Holdings Advocates For Psilocybin As FDA Rejects MDMA For PTSD Treatment
August 14, 2024
Via
Benzinga
Exposures
Product Safety
Tickers
KAYS
Substantial Funding, Debt Resolution, HOPE Dividend, Successful Clinical Trial Towards Accelerated Drug Approval for Bipolar Depression: Nasdaq: NRXP
August 15, 2024
Via
PRLog
Topics
Regulatory Compliance
Exposures
Legal
Product Safety
Regulatory
Tickers
NRXP
Ford Recalls Over 37,000 Vehicles, Including Mustang Mach-E EV SUV, Due To Non-Operational Front Windshield Wipers
August 14, 2024
Via
Benzinga
Topics
Product Recall
Exposures
Legal
Product Safety
Tickers
F
Custics Singapore’s Hautuki Arrives at Incheon International Airport Duty-Free Shop
August 14, 2024
Via
Binary News Network
Exposures
Product Safety
Advanced Hood Cleaning Solutions Enhances Commercial Kitchen Safety with Comprehensive Cleaning and Maintenance Services
August 13, 2024
Via
Get News
Exposures
Product Safety
MDMA Therapy Papers Retracted Amid Ethical Concerns At Lykos Study Site
August 13, 2024
Via
Benzinga
Exposures
Product Safety
FDA Backs Off Joint Study On Kratom And Psychedelics Amidst Public Criticism
August 13, 2024
Via
Benzinga
Exposures
Product Safety
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) Holds Initial Breakthrough Therapy Meeting with FDA, Plans for CYB003 Phase 3 Trial
August 13, 2024
Via
Investor Brand Network
Exposures
Product Safety
Tickers
CYBN
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
99
100
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.